Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis

Clinical and Experimental Immunology

Volumn 149, Issue 1, 2007, Pages 40-47

  Balbi, G ^a   Ferrera, F ^a   Rizzi, M ^a   Piccioli, P ^b   Morabito, A ^b   Cardamone, L ^a   Ghio, M ^a   Palmisano, G L ^a   Carrara, P ^c   Pedemonte, S ^b   Sessarego, M ^a   De Angioletti, M ^d   Notaro, R ^b,e   Indiveri, F ^a   Pistillo, M P ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^e ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

CTLA 4; Single nucleotide polymorphisms; Systemic sclerosis; T ARMS PCR; Thyroiditis

Indexed keywords

AUTOANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; THYROGLOBULIN ANTIBODY; THYROPEROXIDASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HASHIMOTO DISEASE; HUMAN; ITALY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; THYROID GLAND;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOIMMUNE DISEASES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SCLERODERMA, SYSTEMIC;

EID: 34250178113     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03394.x     Document Type: Article

References (37)

1. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2003 2 : 181 91.
2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004 140 : 37 50.
3. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003 29 : 239 54.
4. Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003 29 : 211 37.
5. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002 4 : 99 107.
6. Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003 423 : 506 11.
7. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006 24 : 65 97.
8. Contardi E, Palmisano GL, Tazzari PL et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005 117 : 538 50.
9. Pistillo MP, Tazzari PL, Palmisano GL et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003 101 : 202 9.
10. Carreno BM, Bennett F, Chau TA et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 2000 165 : 1352 6.
11. Gough SC, Walker LS, Sansom DM. CTLA4 gene polymorphism and autoimmunity. Immunol Rev 2005 204 : 102 15.
12. Aguilar F, Torres B, Sanchez-Roman J, Nunez-Roldan A, Gonzalez-Escribano MF. CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum Immunol 2003 64 : 936 40.
13. Chistiakov DA, Savost'anov KV, Turakulov RI, Efremov IA, Demurov LM. Genetic analysis and functional evaluation of the C/T (-318) and A/G (-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease. Clin Immunol 2006 118 : 233 42.
14. Van der Auwera BJ, Vandewalle CL, Schuit FC et al. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry. Clin Exp Immunol 1997 110 : 98 103.
15. Vaidya B, Pearce SH, Charlton S et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxf) 2002 41 : 180 3.
16. Wang XB, Kakoulidou M, Qiu Q et al. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immun 2002 3 : 46 9.
17. Malferrari G, Stella A, Monferini E et al. CTLA4 and multiple sclerosis in the Italian population. Exp Mol Pathol 2005 78 : 55 7.
18. Mora B, Bonamico M, Indovina P et al. CTLA-4 +49 A/G dimorphism in Italian patients with celiac disease. Hum Immunol 2003 64 : 297 301.
19. Almasi S, Erfani N, Mojtahedi Z, Rajaee A, Ghaderi A. Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. Genes Immun 2006 7 : 401 6.
20. Hudson LL, Silver RM, Pandey JP. Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J Rheumatol 2004 31 : 85 7.
21. Rajaee A, Ebrahimi A, Ghiam AF, Kalantari T, Ghaderi A. Exon-1 polymorphism of CTLA-4 gene is not associated with systemic sclerosis in Iranian patients. Rheumatol Int 2006 26 : 687 92.
22. Takeuchi F, Kawasugi K, Nabeta H, Mori M, Tanimoto K. Association of CTLA-4 with systemic sclerosis in Japanese patients. Clin Exp Rheumatol 2002 20 : 823 8.
23. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980 23 : 581 90.
24. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988 15 : 202 5.
25. Ye S, Humphries S, Green F. Allele specific amplification by tetra-primer PCR. Nucl Acids Res 1992 20 : 1152.
26. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000 91 : 865 8.
27. Piccioli P, Serra M, Gismondi V et al. Multiplex tetra-primer amplification refractory mutation system PCR to detect 6 common germline mutations of the MUTYH gene associated with polyposis and colorectal cancer. Clin Chem 2006 52 : 739 43.
28. Svahn J, Capasso M, Lanciotti M et al. The polymorphisms -3 18C > T in the promoter and 49A > G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population. Bone Marrow Transplant 2005 35 (Suppl. 1 S89 92.
29. Holopainen PM, Partanen JA. Technical note. linkage disequilibrium and disease-associated CTLA4 gene polymorphisms. J Immunol 2001 167 : 2457 8.
30. Zaletel K, Krhin B, Gaberscek S, Hojker S. Thyroid autoantibody production is influenced by exon 1 and promoter CTLA-4 polymorphisms in patients with Hashimoto's thyroiditis. Int J Immunogenet 2006 33 : 87 91.
31. Farzati B, Mazziotti G, Cuomo G et al. Hashimoto's thyroiditis is associated with peripheral lymphocyte activation in patients with systemic sclerosis. Clin Exp Rheumatol 2005 23 : 43 9.
32. Chistiakov DA, Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 2003 31 : 21 36.
33. Petrone A, Giorgi G, Mesturino CA et al. Association of DRB1*04-DQB1*0301 haplotype and lack of association of two polymorphic sites at CTLA-4 gene with Hashimoto's thyroiditis in an Italian population. Thyroid 2001 11 : 171 5.
34. Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002 3 : 233 4.
35. Magistrelli G, Jeannin P, Herbault N et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999 29 : 3596 602.
36. Sato S, Fujimoto M, Hasegawa M et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxf) 2004 43 : 1261 6.
37. Johnson GC, Esposito L, Barratt BJ et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001 29 : 233 7.